Roche reported a failure in a pivotal Phase 3 first‑line trial for its oral breast‑cancer candidate, undercutting expectations that the drug could become a major revenue driver. The company said the study did not meet its primary endpoint, marking a material setback for the program and prompting reassessment of the drug’s commercial and development prospects. Investors and partners will be watching Roche for next steps including potential biomarker analyses or alternative development pathways.